Get the Stockscreener App
4.69
2.09%
-0.10
Telomir Pharmaceuticals Inc stock is traded at $4.69, with a volume of 46,750.
It is down -2.09% in the last 24 hours and down -4.48% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company leading the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$4.79
Open:
$4.83
24h Volume:
46,750
Relative Volume:
0.28
Market Cap:
$139.54M
Revenue:
-
Net Income/Loss:
$-13.08M
P/E Ratio:
-10.62
EPS:
-0.4416
Net Cash Flow:
-
1W Performance:
+14.11%
1M Performance:
-4.48%
6M Performance:
+18.43%
1Y Performance:
+0.00%
1-Day Range:
$4.61
$4.9417
1-Week Range:
$4.1448
$5.17
52-Week Range:
$3.11
$20.72
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
4.69 | 139.54M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 58.9% in December - MarketBeat
Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) biggest owners are retail investors who got richer after stock soared 13% last week - Yahoo Finance
Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded - Simply Wall St
Barclays PLC Buys 5,367 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Geode Capital Management LLC Has $1.53 Million Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals reports breakthrough in progeria study By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals confirms lifespan restoration in Progeria preclinical model with Telomir-1 - MSN
Telomir Pharmaceuticals reports breakthrough in progeria study - Investing.com
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging) - AccessWire
State Street Corp Acquires 17,967 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Short Interest in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Expands By 22.9% - MarketBeat
Telomir Pharmaceuticals Confirms Copper-Binding Capabilities of Telomir-1 and Expands Pipeline into Wilson’s Disease - Defense World
Telomir Pharmaceuticals Expands Pipeline, Confirms Copper-Binding Potential of Telomir-1 for Wilson’s Disease - ChemAnalyst
Telomir-1 shows promise in copper binding studies - Investing.com
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease - Chronicle-Tribune
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease - Yahoo Finance
Telomir Pharmaceuticals appoints new accounting firm - Investing.com India
Telomir Pharmaceuticals Raises $1 Million in Premium-Priced Stock Deal, Boosting Age-Reversal Research - Citybuzz
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation - Nasdaq
Telomir Pharmaceuticals enters into stock purchase agreement - MSN
Telomir Pharmaceuticals secures $1 million equity funding - Investing.com
Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - AccessWire
Telomir Pharmaceuticals Secures Premium-Priced Funding After Breakthrough Anti-Aging Drug Results - StockTitan
Telomir Pharmaceuticals secures $1 million in equity funding By Investing.com - Investing.com Canada
Telomir Pharmaceuticals secures $1 million in equity funding - Investing.com
(TELO) Technical Data - Stock Traders Daily
Stocks In Play: Renegade Gold Inc. - Barchart
Telomir-1 shows promise in diabetes preclinical study By Investing.com - Investing.com Nigeria
Unifor And PPWC Target Kruger, Inc. To Begin Western Pattern Bargaining - Barchart
Stocks In Play: Yukon Metals Corp - Barchart
Telomir-1 shows promise in diabetes preclinical study - Investing.com India
Deadline To Apply For A Special Ballot Approaches - Barchart
Media AdvisoryDeputy Prime Minister's Itinerary For Wednesday, December 4, 2024 - Barchart
AME ANNOUNCES 2024 AWARD RECIPIENTS - Barchart
Perimeter Provides Update on Canada Postal Strike and Mailing of the Company's 2024 Annual General Meeting Materials - Barchart
Ontario Lottery And Gaming CorporationMidDay Lottery Winning NumbersDec. 3, 2024 - Barchart
Stocks In Play: PyroGenesis Inc. - Barchart
Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | ProQR Therapeutics, Kowa Pharmac, Trefoil Therapeutics, Alcon Inc., Emmecell - Barchart
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Preclinical Study - newsbreak.com
Telomir Pharmaceuticals' Shares Rally After Positive Results for Diabetes Treatment - MarketWatch
Gastroesophageal Adenocarcinoma Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., Merck, Taiho Pharma - Barchart
Telomir Pharmaceuticals Achieves Breakthrough in Type 2 Diabetes Treatment with Novel Age-Reversal Drug - Barchart
Enbridge Inc. Announced 3% Quarterly Dividend Increase For 2025 - Barchart
Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1 - AccessWire
Telomir Pharmaceuticals reports breakthrough in diabetes study - Investing.com
Telomir Pharmaceuticals reports breakthrough in diabetes study By Investing.com - Investing.com Canada
Stocks In Play: Southern Energy Corp. - Barchart
Telomir Pharmaceuticals Inc (TELO) Recovers 37.62% From Low: Are We There Yet? - Stocks Register
Telomir Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Eton PharmaSmall Cap That's Climbing - Barchart
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):